Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.10), Zacks reports.
Lakewood-Amedex Biotherapeutics Trading Down 7.2%
Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.02 during mid-day trading on Wednesday, reaching $0.20. 351,517 shares of the stock were exchanged, compared to its average volume of 7,398,063. The company has a market cap of $471,630.00 and a price-to-earnings ratio of -0.04. The firm has a 50-day simple moving average of $0.92 and a 200 day simple moving average of $5.23. Lakewood-Amedex Biotherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $98.20.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on LABT. Wall Street Zen lowered shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. Finally, HC Wainwright assumed coverage on shares of Lakewood-Amedex Biotherapeutics in a research note on Wednesday, October 28th. They set a “buy” rating for the company. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold”.
View Our Latest Analysis on LABT
Lakewood-Amedex Biotherapeutics Company Profile
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.
Featured Stories
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
